Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist
Stopped early
Conditions studied: Multiple Sclerosis
In brief
* The investigators are conducting a magnetic resonance imaging (MRI) study comparing two MRI contrast agents in people with clinically isolated syndrome and relapsing remitting multiple sclerosis (MS). MS is a disease that affects the white matter and gray matter in the brain. MRI is used as a gold standard to visualize the degenerative changes in the brain and spine. The neurologist will usually order an MRI to confirm the diagnosis of MS using conventional imaging methods. These images reveal two main pieces of information regarding (a) the location of the lesions and (b) the status of the lesions. While the location of the lesions directly correlates with the clinical symptoms, the information about the status of the lesions informs the neurologist whether the lesion is new (active) or old (chronic). * This ability to differentiate new and old lesions requires the use of a contrast agent. Currently, used agents reveal some lesions but it is unclear if they reveal the full extent of the disease. In new lesions, there may be a leakiness in the blood vessels and if the contrast agent leaks out then the investigators can see this. In healthy controls, the blood brain barrier is usually intact and this leak does not happen. One open question is: "can the extravasation of the contrast agent to the brain precede the major tissue damage that we see in the structural MRI?" * Recently, a new FDA approved contrast agent (Gadavist) has been released and has enhanced characteristics in terms of affecting the MR signal resulting in a better contrast in the image and therefore, better diagnosis of the status of the disease. Given its high relaxivity, a small amount of Gadavist may show a better signal enhancement affected tissue for multiple sclerosis patients. The investigators hypothesize that Gadavist will reveal more tissue damage (lesions) than Magnevist and, therefore, may present a better tool for early diagnosis of brain damage. * The investigators' goal in this research project is to see if the newer contrast agent is able to detect changes and differentiate healthy from affected tissue in the white matter and gray matter earlier than current contrast agents so that detection can be possible before major damage occurs to the tissue. Each person will be scanned initially with one agent and then between 8 and 30 days later with the other agent. The MR data processing results will be compared to check the efficacy of each contrast agent.
Key facts
- Study ID
- NCT01836055
- Run by
- Wayne State University
- People needed
- 19
- Starts
- 2012-01-01
- Expected to finish
- 2014-02-01
- Last updated by the study team
- 2014-12-09
Who can join
Age: 20 and older, up to 59. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- MS Patients:
- Patients who suffer from clinically definite MS with a RR phenotype or CIS
- Age range from 20-59 years old
- Not pregnant or nursing
- Able to understand and sign a consent form
- No contraindication to MRI and contrast agent
- Controls:
- Control is a healthy volunteer
- Aged from 20-59 years old
- Not pregnant or nursing
- Able to understand and sign a consent form
- No contraindication to MRI and contrast agent
You may not qualify if…
- MS Patients:
- History of other major illness such as diabetes, chronic renal disease, a prior known neurological disorder other than MS or substances abuse
- Currently receiving chemo therapy, on dialysis
- Known contraindication to MRI such as pacemaker, pregnancy, other non-MR compatible implanted device
- Allergic to MRI contrast Patients with moderate to severe kidney disease that have impaired ability to filter the contrast agents (serum creatinine > 1.8 mg/dL).
- Younger than 20 or older than 59
- Pregnancy or nursing
- Unable to understand and sign a consent form
- Controls:
- History of other major illness such as diabetes, chronic renal disease, a prior known neurological disorder or substances abuse
- Currently receiving chemo therapy, on dialysis
- Known contraindication to MRI such as pacemaker, pregnancy, other non-MR compatible implanted device
- Allergic to MRI contrast Controls with moderate to severe kidney disease that have impaired ability to filter the contrast agents (serum creatinine > 1.8 mg/dL).
- Younger than 20 or older than 59
- Pregnancy or nursing
- Unable to understand and sign a consent form
Where it is running
- Wayne State University — Detroit, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.